ClinicalTrials.gg
Active, not recruitingNCT07161687HIZUpdated Nov 6, 2026

A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

An observational study in Hemophilia A or B, sponsored by Pfizer. Active, not recruiting at 1 site in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Observational

How we know

Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.

Planned enrollment
8th of 13
50 · median 52
Started
2025
with 2 others
Observational
13 of 47
1 open now
Registered
45th of 47
by date

Among the 47 studies in Hemophilia A by Pfizer, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2025, is one of 13 observational ones, and was the 45th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hemophilia A by Pfizer, or all of them as a file.
02

Study summary

A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Read the detailed description

The objective of this study is to assess the safety of this drug under actual usage conditions in patients with congenital hemophilia who do not have inhibitors.

The observation period will be up to three years. However, for cases in which administration of the drug is discontinued, information will be collected up to the point of discontinuation.

03

Conditions studied

  • Hemophilia A or B

Browse trials for

Keywords

  • Marstacimab,Hympavzi,Hemophilia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients who have received at least one dose of this drug after the launch of this drug.

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  • Patients who have received at least one dose of this drug after the launch of this drug
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Marstacimab

    hemophilia patients without inhibitor

    Drug: Marstacimab

Interventions

  • For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate response, the dose may be increased to 300 mg once weekly for subcutaneous administration.

    Also known as: Hympavzi

06

What researchers measure

Primary outcomes

  1. Number of the participants with adverse drug reactions

    An adverse drug reaction (ADR) was a treatment-related adverse event, and any untoward medical occurrence attributed to Himpavzi in a participant who received Himpavzi. A serious adverse drug reaction (SADR) was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to Himpavzi was assessed by the physician.

    Time frame: The evaluation period is from the first dose of Himpavzi up to 156 weeks (3 years).

07

Study locations

1 site
  • Pfizer
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2030, 52 months after the start.

Of 53 industry-sponsored observational studies under Hemophilia A, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 79. This study's planned 52 months is below that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Apr 2030 → Mar 2030 and completion Apr 2030 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 9, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Mar 28, 2030was Apr 2030
CompletionEst.
Mar 28, 2030was Apr 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 11, 2030→Mar 28, 2030
Nov 6, 2026
Study completion
Apr 11, 2030→Mar 28, 2030
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Apr 11, 2030→Mar 28, 2030
    Study completion Apr 11, 2030→Mar 28, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07161687
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Oct 30, 2025
Primary completion
Mar 28, 2030 (estimated)
Completion
Mar 28, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion